

ASX Release

JAPANESE PATENT GRANTED FOR TALi PLATFORM

TALi Digital Limited (ASX: TD1) (TALi or The Company), a leading digital health business is pleased to announce it has received confirmation that the company has been granted its first Japanese patent by the Japan Patent Office (JPO).

HIGHLIGHTS

- Japanese Patent No. 6782880. Expiry date March 31, 2035 (the patent claims have a priority date of March 31, 2015, i.e. the term of the granted monopoly is 20 years).
- The granting of the patent strengthens TALi's intellectual property position (IP) in Japan, the developed world's third largest market for attention related treatments
- The patent covers the TALi DETECT and TALi TRAIN products as well as the soon to be released TALi maintenance program
- The Japanese Patent follows the granting of a USA patent and China Trademark secured earlier in 2020 providing significant protection for the Company's IP portfolio
- The patent provides the pathway for TALi to enter Japanese market via a partnership model

The patent (Japanese Patent No. 6782880) has an expiry date of March 31, 2035 (the patent claims have a priority date of March 31, 2015, i.e. the term of the granted monopoly is 20 years) and the claims of the patent cover the TALi DETECT and TALi TRAIN products as well as the soon to be released TALi maintenance program.

To the best of our knowledge, this is the first time that a patent has been granted in Japan for a cognitive assessment and training system, capable of improving attentional skills for sustained periods.

Japan is the world's third-largest market for ADHD treatments and is growing at more than 20 percent annually¹. ADHD is a major issue amongst the Japanese population of 15 Million children under 15 years².

Of most importance to TALi are the dynamics of the Japanese market where non-pharmaceutical based approaches are the preference. A CCHR Report 'ADHD labelling and treatment of Children in Japan' highlighted that treatment with medication for attention-deficit/hyperactivity disorder (ADHD) is less favourable than psychosocial treatment³.

The report goes on to recommend "that psychotropic drugs are prescribed as a measure of last resort and only after an individualised assessment of the best interests of the child" demonstrating the difficulty

¹ 2018, CCHR Report: ADHD labeling and treatment of children in Japan, page 3

² Statistics Bureau of Japan. 2020. "Chapter 2 Population." Statistical Handbook of Japan 2020. <https://www.stat.go.jp/english/data/handbook/c0117.html> Accessed 29/9/2020.

³ 2018, CCHR Report: ADHD labeling and treatment of children in Japan, page 11

For personal use only

in obtaining regulatory approval for paediatric medications in Japan and reinforcing the opportunity and potential market advantage for digital therapeutics such as the TALi platform technology.

These key dynamics in the Japanese market provide significant opportunity for the introduction of non-invasive digital tests such as TALi DETECT and treatments such as TALi TRAIN. The granting of this patent combined with the granting of a US patent earlier in 2020 ([see announcement 21 April 2020](#)) further highlights the growing value of the TALi platform intellectual property portfolio. The Company continues to progress discussions with commercial partners to enter the Japanese market.

TALi Digital Managing Director Glenn Smith said *“The granting of the patent secures TALi’s intellectual property position and paves the way for the Company to enter the Japanese market via a partnership model. With over 15 million children in Japan, under the age of 15 years, the country represents a large potential market for the range of TALi cognitive assessment tools. The ability to leverage our patents strengthens our software in multiple regions and highlights the global opportunity of our product suite.”*

Release authorised by:

TALi Digital Board of Directors

CONTACT

Corporate

Glenn Smith
TALi Digital Managing Director
p. 1300 082 013
e. investors@talidigital.com

Investors

Craig Sainsbury
Market Eye
p: +61 428 550 499
e. craig.sainsbury@marketeye.com.au

About TALi Digital

TALi Digital Limited (ASX:TD1) a leading digital health business is seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills. Learn more at talihealth.com.au.